Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
CAMBRIDGE, Mass., February 25, 2008 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, announced today that three abstracts have been accepted for presentation at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) to be held in Milan, Italy, April 23 - 27, 2008. Full abstracts can now be viewed at the EASL website at http://www.easl.ch.
David Standring, Ph.D., Executive Vice President, Biology at Idenix Pharmaceuticals, will present "In Vitro Activity and Pharmacologic Properties of Two Novel Series of HCV Protease Inhibitors" in an oral presentation session at 6:15 p.m. CET on Thursday, April 24, 2008.
Dr. Standring will also present, "Potent Antiviral Activity of Second Generation Nucleoside Inhibitors, IDX102 and IDX184, in HCV-Infected Chimpanzees" in an oral presentation session at 5:30 p.m. CET on Friday, April 25, 2008.
Erika Cretton-Scott, Ph.D., Director, Preclinical Pharmacology at Idenix Pharmaceuticals, will present "In Vitro Antiviral Activity and Pharmacology of IDX184, a Novel and Potent Inhibitor of HCV Replication" in a poster session beginning on Thursday, April 24, 2008.
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus and human immunodeficiency virus (HIV). For further information about Idenix, please refer to http://www.idenix.com.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward- looking statements can be identified by implied discussions with respect to the company's clinical development programs in hepatitis C, or any potential pipeline candidates for the treatment of hepatitis C. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, pre-clinical studies and/or clinical trials, including additional data relating to the ongoing pre- clinical studies and/or clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaboration with Novartis Pharma AG; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 31, 2006 and the Quarterly Report on Form 10- Q for the quarter ended September 30, 2007, each as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.
All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.
Idenix Pharmaceuticals' Contacts:
Media: Teri Dahlman (617) 995-9905
Investors: Amy Sullivan (617) 995-9838
CONTACT: Media: Teri Dahlman, +1-617-995-9905, or Investors: Amy Sullivan,+1-617-995-9838, both of Idenix Pharmaceuticals, Inc.
Ticker Symbol: (NASDAQ-NMS:IDIX)
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: February 2008